World / Health & Beauty
AngioScore Launches New Longer And Larger AngioSculpt(R) Devices For Treatment Of Peripheral Artery Disease
14.07.2008 08:11
medicalnewstoday.com
AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced the launch of new longer and larger AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD). The new devices have received U.S.
World
Cardiology
Calistoga Pharmaceuticals Initiates First Oncology Clinical Trial Of Novel PI3K Delta Inhibitor, CAL-101
14.07.2008 08:11
medicalnewstoday.com
Calistoga Pharmaceuticals, Inc., a company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, announced the initiation of a Phase 1 clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase (PI3K) delta inhibitor, in patients with hematologic cancer. "We at Calistoga are very pleased to be entering our first oncology trial.
World
Cancer
Ravers lose sight at Russian laser show
14.07.2008 08:01
reuters.com
MOSCOW (Reuters) - Dozens of partygoers at an outdoor rave near Moscow last week have lost partial vision after a laser light show burned their retinas, Russian health officials said on Monday.
World
Health & Beauty
Theragenics Corporation(R) Engages Men In A National Debate On Prostate Cancer
14.07.2008 07:15
medicalnewstoday.com
Theragenics Corporation, a medical device Company serving the prostate cancer and surgical markets (NYSE: TGX), is challenging men to engage in a national debate surrounding the treatment of the disease that will affect one in six of them - prostate cancer. This week, the Company announced its latest campaign to promote awareness of proven prostate cancer treatment options, "The Great Prostate Debate.
World
Urology
Repros Therapeutics Inc. Announces That Proellex Significantly Reduces Pain In A U.S. Phase 2 Trial In Women With Moderate To Severe Endometriosis
14.07.2008 07:15
medicalnewstoday.com
Repros Therapeutics Inc. (NasdaqGM:RPRX) released positive results from an interim analysis of its U.S. Phase 2 endometriosis trial. The study was designed to assess the effect of Proellex on symptom control in women with endometriosis who have moderately severe to severe pain. The data show that pain, the most troublesome symptom associated with endometriosis, is statistically and clinically meaningfully reduced in one to two months of treatment compared with placebo.
World
Urology
Kronos Optimal Health Company Aims To Stop Diabetes Before It Starts
14.07.2008 07:14
medicalnewstoday.com
More than 54 million American adults have prediabetes, but many of those people may never have to live with diabetes and all of its health complications thanks to a new prediabetes lifestyle management course created by Kronos Optimal Health Company. It is estimated that 60 percent of prediabetics can avoid diabetes altogether with manageable lifestyle choices.
World
Diabetes
TheraGenetics Licenses Intellectual Property Related To Predicting Patient Response To Antidepressant Therapy
14.07.2008 07:14
medicalnewstoday.com
TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced that it has completed an agreement with the Centre for
World
Depression
Lutronic Announces FDA Clearance And Immediate Availability Of Its ECO2, The First Multi-Functional Fractional CO2 Laser System
14.07.2008 07:14
medicalnewstoday.com
Lutronic, Inc., one of the world's leading developers and manufacturers of aesthetic and medical laser systems, announced that it has received regulatory clearance from the U.S. FDA (Food and Drug Administration) for the eCO2 system.
World
Plastic Surgery
CardioTech Receives FDA Approval For Export Of Second Graft Size For CardioPass Clinical Trial
14.07.2008 07:14
medicalnewstoday.com
CardioTech International, Inc. (AMEX: CTE), a leading developer and manufacturer of advanced biomaterials for a broad range of medical devices, announced that it has received the necessary U.S. Food and Drug Administration ("FDA") approval to export its 4mm graft in further support of the ongoing European clinical trial of CardioPass™ , the Company's proprietary synthetic coronary bypass graft.
World
Cardiology
Power3 Medical Products Advances The Diagnostic Capabilities Of The Company's Alzheimer's Disease Biomarkers
14.07.2008 07:13
medicalnewstoday.com
Power3 Medical Products, Inc. (OTCBB:PWRM) announced the filing of a US Patent application for the diagnosis of multiple forms of Alzheimer's disease by monitoring a panel of protein biomarkers in human blood serum. This latest filing further extends the reach of the recently filed US Utility Patent Application that identified 47 protein biomarkers useful in the early diagnosis of Alzheimer's disease.
World
Alzheimer's Disease
No alcohol for young drivers call
14.07.2008 07:04
bbc.co.uk
The chief medical officer for England says the legal blood alcohol limit should be reduced to zero for drivers aged 17 to 20.
World
Health & Beauty
Sleeping soundly 'boosts memory'
14.07.2008 07:04
bbc.co.uk
A refreshing night's sleep may be the best way to boost memory, a study suggests.
World
Health & Beauty
Affymax Completes Enrollment In PEARL 1, The First Of Four Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patient
14.07.2008 06:15
medicalnewstoday.com
Affymax, Inc. (Nasdaq:AFFY) announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patients. PEARL 1 (Phase 3 Evaluation of Hematide for Anemia Correction in Chronic Renal Failure) is fully enrolled with over 475 non-dialysis patients from over 70 sites in the United States.
World
Urology
California Pharmacies Win Court Order To Halt 10 Percent Cut For Medi-Cal Prescription Drugs
14.07.2008 06:14
medicalnewstoday.com
Late Friday, pharmacy providers were notified that a three judge panel of the Ninth Circuit Court of Appeals had acted to halt the ten percent payment cuts for prescription drugs dispensed under the Medi-Cal Program. The action was made in response to an emergency appeal in the case, Independent Living Center of Southern California, et.al. v. Shewry, to challenge a lower court ruling that the plaintiffs did not have standing to sue under the Supremacy Clause of the U.S. Constitution.
World
Pharmaceutics
SinuCleanse Introduces Kids Mist
14.07.2008 06:14
medicalnewstoday.com
Makers of the SinuCleanse® line of nasal washing products, today announced a product for children, the Kids Mist ™. With the recent ban by the Food and Drug Administration on many over-the-counter cough and cold medicines for children, parents have been left with few options for easing kids' sinus symptoms.
World
Children Diseases
English